Geron Biotechnology

Nobel Prize-winning discoveries launched their mission to change lives by changing the course of blood cancer.

As Geron advances towards FDA approval (with their first drug, RYTELO), their website needed to be a flexible, editorial driven experience in support of RYTELO, as well as company leadership, manufacturing, and communications executive to plan, and shape the content to maximize impact, and value.

Geron's brand was enhanced to include a series of custom gradients, and infographics to emphasize their bold nature, and indicate milestones on their journey to commercialization, and beyond.

Outcome

FDA approved RYTELO on June 6, 2024

Year

2023

Industry

Biotechnology Research

Client

Geron Biotechnology

Type

Website, Content library, Infographics

Visit website

geron.com
Geron needs to impress Wall Street, and by displaying Research & Development first, showcases their progress. By highlighting their people and clinical trials, showcases their experience, and impact. A mobile-first design, gives modern investors direct access to Geron's critical updates, anywhere, and anytime. A podcast was suggested to share progress, event updates, and provide opportunities for future interviews.
Website, Content library, Infographics
Custom gradients, and infographics emphasized the pioneering spirit of Geron's culture, and dynamic approach to communications. Building on Geron's already bold color palette, the flame represented in their logo was introduced to each graphic to reinforce how a flame is constantly evolving, rarely the same shape twice.

Animation was designed to explain how Telomerase operates in the bloodstream. The final video was used to showcase these advancements to investors, and the media, as well as event experiences. R&D Pipeline was reimagined to smoothly flow between the desktop, tablets, and mobile.

This is some text inside of a div block.
This is some text inside of a div block.

More projects

Year

Client

Industry

Type